Logo image of SDGR

SCHRODINGER INC (SDGR) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:SDGR - US80810D1037 - Common Stock

16.42 USD
+0.1 (+0.61%)
Last: 1/21/2026, 8:00:03 PM
16.5 USD
+0.08 (+0.49%)
After Hours: 1/21/2026, 8:00:03 PM

SDGR Key Statistics, Chart & Performance

Key Statistics
Market Cap1.21B
Revenue(TTM)256.95M
Net Income(TTM)-175.99M
Shares73.66M
Float62.80M
52 Week High28.47
52 Week Low15.99
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-2.41
PEN/A
Fwd PEN/A
Earnings (Next)02-24
IPO2020-02-06
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Technology
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Technology
SDGR short term performance overview.The bars show the price performance of SDGR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20 -25

SDGR long term performance overview.The bars show the price performance of SDGR in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30

The current stock price of SDGR is 16.42 USD. In the past month the price decreased by -7.02%. In the past year, price decreased by -33.44%.

SCHRODINGER INC / SDGR Daily stock chart

SDGR Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

SDGR Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to SDGR. No worries on liquidiy or solvency for SDGR as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SDGR Financial Highlights

Over the last trailing twelve months SDGR reported a non-GAAP Earnings per Share(EPS) of -2.41. The EPS increased by 0.82% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -26.92%
ROE -54.77%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%13.46%
Sales Q2Q%53.94%
EPS 1Y (TTM)0.82%
Revenue 1Y (TTM)32.9%

SDGR Forecast & Estimates

15 analysts have analysed SDGR and the average price target is 25.5 USD. This implies a price increase of 55.3% is expected in the next year compared to the current price of 16.42.

For the next year, analysts expect an EPS growth of 19.11% and a revenue growth 24.45% for SDGR


Analysts
Analysts82.67
Price Target25.5 (55.3%)
EPS Next Y19.11%
Revenue Next Year24.45%

SDGR Ownership

Ownership
Inst Owners109.2%
Ins Owners2.64%
Short Float %15.18%
Short Ratio10.33

About SDGR

Company Profile

SDGR logo image Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. The company is headquartered in New York City, New York and currently employs 891 full-time employees. The company went IPO on 2020-02-06. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The firm's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.

Company Info

SCHRODINGER INC

1540 Broadway, 24th Floor

New York City NEW YORK 10036 US

CEO: Ramy Farid

Employees: 891

SDGR Company Website

SDGR Investor Relations

Phone: 15032991150

SCHRODINGER INC / SDGR FAQ

What does SCHRODINGER INC do?

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. The company is headquartered in New York City, New York and currently employs 891 full-time employees. The company went IPO on 2020-02-06. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The firm's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.


What is the current price of SDGR stock?

The current stock price of SDGR is 16.42 USD. The price increased by 0.61% in the last trading session.


Does SDGR stock pay dividends?

SDGR does not pay a dividend.


What is the ChartMill rating of SCHRODINGER INC stock?

SDGR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the market capitalization of SDGR stock?

SCHRODINGER INC (SDGR) has a market capitalization of 1.21B USD. This makes SDGR a Small Cap stock.


What is the Short Interest ratio of SCHRODINGER INC (SDGR) stock?

The outstanding short interest for SCHRODINGER INC (SDGR) is 15.18% of its float.